is praluent a pcsk9 inhibitor?
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. Coronary heart disease, more often referred to as cardiovascular disease (CVD) today, is a leading cause of illness and death in the United States.